Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

 v2.3.0.11
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands
 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Cash flows from operating activities:    
Net loss $ (14,466) $ (37,365)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,702 2,956
Common shares contribution to 401(k) 1,046 905
Share-based compensation expense 4,056 2,081
Accrued interest on interest bearing obligations 496 164
Revaluation of warrant liabilities (2,850) (1,691)
Warrant modification expense 0 4,500
Amortization of discount on long-term debt 661 0
Unrealized loss on foreign currency exchange 1,876 0
Unrealized gain on foreign exchange options (157) 0
Other non-cash adjustments 11 12
Changes in assets and liabilities affecting cash:    
Receivables 9,805 (1,285)
Prepaid expenses and other assets (1,601) (863)
Accounts payable and accrued liabilities (2,505) 294
Deferred revenue (12,382) (1,979)
Other liabilities (25) (239)
Net cash used in operating activities (13,333) (32,510)
Cash flows from investing activities:    
Net purchase of property and equipment (2,253) (254)
Net cash used in investing activities (2,253) (254)
Proceeds from issuance of long-term debt 20,102 0
Proceeds from issuance of common shares 9,910 25,456
Payment for modification of warrants 0 (4,500)
Net cash provided by financing activities 30,012 20,956
Effect of exchange rate changes on cash (573) 0
Net increase in cash and cash equivalents 14,426 (11,808)
Cash and cash equivalents at the beginning of the period 37,304 23,909
Cash and cash equivalents at the end of the period 51,157 12,101
Cash paid during the half of 2011 for:    
Income taxes 15 16
Non-cash investing and financing activities:    
Discount on long-term debt (8,899) 0
Issuance and extinguishment of warrant liabilities 0 1,767
Interest added to principal balance on Novartis note $ 170 $ 164